Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

BCBA/JNJ stock hub

BCBA/JNJ has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCBA/JNJis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

742T

Buenos Aires Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BCBA/JNJ

In the news

Latest news · BCBA/JNJ

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E18.6

P25 14.1P50 17.9P75 19.4

Trailing P/E25.7

P25 25P50 30P75 39

ROE26.4

P25 6.8P50 15.6P75 45.1

ROIC19.9

P25 9P50 19.1P75 21.2

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCBA/JNJ market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

238

Groups with data

Currency

USD

Showing 238 of 238 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	AR
Employees	138,200
Employees Change	6,200%
Employees Change Percent	4.7
Enterprise value	ARS 787.9T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	ARDEUT110236
Last refreshed	2026-05-10
Market cap	ARS 742T
Price	ARS 21,960
Price currency	ARS
Rev Per Employee	957,694,992.08x
Sector	Healthcare
Sic	2834
Symbol	bcba/JNJ
Website	https://www.jnj.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.89%
EV Earnings	27.26x
EV/EBIT	21.27x
EV/EBITDA	16.39x
EV/FCF	32.25x
EV/Sales	5.87x
FCF yield	3.29%
Forward P/E	18.56x
P/B ratio	6.65x
P/E ratio	25.68x
P/S ratio	5.61x
PE Ratio10 Y	45.82x
PE Ratio3 Y	18.63x
PE Ratio5 Y	21.16x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	27.59%
EBITDA Margin	35.62%
FCF margin	18.46%
Gross margin	68.04%
Gross Profit	ARS 90T
Gross Profit Growth	6.69%
Gross Profit Growth Q	9.85%
Gross Profit Growth3 Y	6.7%
Gross Profit Growth5 Y	3.28%
Net Income	ARS 28.9T
Net Income Growth	-3.53%
Net Income Growth Q	-52.41%
Net Income Growth3 Y	18.25%
Net Income Growth5 Y	6.84%
Pretax Margin	25.88%
Profit Margin	21.83%
Profit Per Employee	ARS 209.1M
ROA	8.42
Roa5y	8.04
ROCE	18.57
ROE	26.42
Roe5y	24.21
ROIC	19.95
Roic5y	23.67

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	72.32%
Cagr15y	62.35%
Cagr1y	83.55%
Cagr20y	47.92%
Cagr3y	66.91%
Cagr5y	67.33%
Div CAGR10	71.93%
Div CAGR3	116.73%
Div CAGR5	87.29%
EPS Growth	-3.89
EPS Growth Q	-52.86
EPS Growth3 Y	21.64
EPS Growth5 Y	8.81
FCF Growth	-12.7%
FCF Growth Q	-56.64%
FCF Growth3 Y	3.14%
FCF Growth5 Y	-3.13%
OCF Growth	-7.72%
OCF Growth Q	-39.77%
OCF Growth10 Y	1.93%
OCF Growth3 Y	3.76%
OCF Growth5 Y	-1.17%
Revenue Growth	7.87x
Revenue Growth Q	9.91x
Revenue Growth3 Y	7.55x
Revenue Growth5 Y	2.73x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	ARS 0.49
Assets	ARS 275.9T
Cash	ARS 30.3T
Current Assets	ARS 82.8T
Current Liabilities	ARS 80.7T
Debt	ARS 75.5T
Debt EBITDA	ARS 1.59
Debt Equity	ARS 0.68
Debt FCF	ARS 3.09
Equity	ARS 111.5T
Interest Coverage	25.59
Liabilities	ARS 164.4T
Long Term Assets	ARS 193.2T
Long Term Liabilities	ARS 83.7T
Net Cash	ARS -45.2T
Net Cash By Market Cap	ARS -6.1
Net Debt EBITDA	ARS 0.96
Net Debt Equity	ARS 0.41
Net Debt FCF	ARS 1.85
Tangible Book Value	ARS -22.6T
Tangible Book Value Per Share	ARS -9,379
WACC	5.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.03
Inventory Turnover	2.26
Net Working Capital	ARS -4.3T
Quick ratio	0.69
Working Capital	ARS 2T
Working Capital Turnover	ARS 16,436

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.29%
Dividend Growth	42.11%
Dividend Growth Years	24%
Dividend per share	ARS 297
Dividend Years	29
Dividend Yield	1.36%
Ex Div Date	2026-02-24
Last Dividend	ARS 76.71
Payout Frequency	Quarterly
Payout Ratio	59.52%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	22,975.18%
1Y total return	83.48%
200-day SMA	20,166.3
3Y total return	365.15%
50-day SMA	23,283
50-day SMA vs 200-day SMA	50over200
5Y total return	1,211.38%
All Time High	24,750
All Time High Change	-11.27%
All Time High Date	2026-03-02
All Time Low	2.18
All Time Low Change	1,009,091.18%
All Time Low Date	2001-04-26
ATR	477.2
Beta	0.26
Ch YTD	4.42
High	22,200
High52	24,750
High52 Date	2026-03-02
High52ch	-11.27%
Low	21,900
Low52	11,225
Low52 Date	2025-05-14
Low52ch	95.64%
Ma50ch	-5.68%
Price vs 200-day SMA	8.89%
RSI	35.8
RSI Monthly	70.5
RSI Weekly	52.79
Sharpe ratio	2.22x
Sortino ratio	3.53
Total Return	1.07%
Tr YTD	4.95
Tr15y	143,445.43%
Tr1m	-7.11%
Tr1w	-1.92%
Tr3m	-7.62%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	ARS 36.5T
Operating Income Growth	17.5
Operating Income Growth Q	4.05
Operating Income Growth3 Y	6.76
Operating Income Growth5 Y	4.61
Operating margin	27.59

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,403,389,742%
Net Borrowing	2,517,584,250,600
Shares Insiders	0.04%
Shares Institutions	76.3%
Shares Qo Q	0.25%
Shares Yo Y	0.29%
Short Ratio	2.44

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	ARS 22.6T
Average Volume	12,966.75x
Bv Per Share	46,335
CAPEX	ARS -7T
Ch10y	20,022.2
Ch15y	116,293.7
Ch1m	-7.11
Ch1w	-1.92
Ch1y	80
Ch20y	186,270.2
Ch3m	-8.08
Ch3y	344.2
Ch5y	1,131.6
Ch6m	19.93
Change	-0.23%
Change From Open	-1.04
Close	22,010
Days Gap	0.82
Depreciation Amortization	10,818,618,987,995
Dollar Volume	228,845,160
Earnings Date	2026-04-14
EBIT	ARS 36.5T
EBITDA	ARS 47.1T
EPS	ARS 11,861
F Score	5
FCF	ARS 24.4T
FCF EV Yield	3.1x
Financing CF	-21,194,517,077,500
Fiscal Year End	December
Founded	1,886
Goodwill	67,916,031,133,686
Graham Number	7969.3521
Graham Upside	-63.71
Income Tax	ARS 5.4T
Investing CF	-33,418,689,327,500
Is Primary Listing	0
Last Earnings Date	2026-04-14
Last Report Date	2026-03-29
Last Split Date	2022-11-17
Last Split Type	Forward
Lynch Fair Value	ARS 5,849
Lynch Upside	-73.37
Ma150	21,625.5
Ma150ch	1.55%
Ma20	22,666
Ma20ch	-3.11%
Net CF	-23,055,612,965,000
Next Earnings Date	2026-07-14
Open	22,190
P FCF Ratio	30.38
P OCF Ratio	23.62
Payment Date	2026-03-10
Position In Range	20
Ppne	32,546,769,728,590
Price Date	2026-05-08
Price EBITDA	ARS 15.74
Relative Volume	0.8x
Revenue	132,353,447,905,000x
SBC By Revenue	1.42x
Share Based Comp	1,876,204,415,000
Tax By Revenue	4.05x
Tax Rate	15.64%
Tr20y	251,328.66%
Tr6m	21.01%
Volume	10,421
Z Score	4.38

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

BCBA/JNJ dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.4%

$297 annual per share

Payout ratio

+59.5%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+87.3%

24 consecutive years of growth

Total shareholder yield

+1.1%

Next ex-dividend date: 2026-02-24

Performance

BCBA/JNJ stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCBA/JNJ?

Insider, institutional, and short-interest positioning.

Institutional ownership

+76.3%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BCBA/JNJ momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

35.8

Neutral momentum band

Price vs 200-day MA

+8.9%

50/200-day relationship not available

Beta (5Y)

0.26

Less volatile than the market

Sharpe ratio

2.22

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCBA/JNJ

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bcba/JNJ stock rating?

bcba/JNJ is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bcba/JNJ analysis?

The full report lives at /stocks/bcba/JNJ/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bcba/JNJ?

The latest report frames bcba/JNJ around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bcba/JNJ page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.